Sagent Pharma (SGNT) has received the approval of Zoledronic Acid Injection 4mg/100ml, the generic form of the bisphosphonate Zometa, to be packed in a ready-to-use premix IV bag.
The new packaging for Zoledronic Acid Injection features Sagent's PreventIV Measures packaging and labeling, which has been designed to decrease medication errors and are similar to packaging of all other products of its portfolio.
Sagent board chairman and chief executive officer Jeffrey Yordon said that the company is pleased to receive the approval of Zoledronic Acid Injection 4mg in the enhanced packaging option of a ready-to-use premix bag.
As per the IMS data for the 12 months ending June 2013, the US market for Zoledronic Acid Injection 4mg stood at nearly $500m.
The injection is indicated to treat patients suffering from hypercalcemia of malignancy, multiple myeloma and documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.
